Latest news

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…

GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market

Challenge Debiopharm-Inartis récompense les six finalistes 2017

Sonnedix acquires Aloe Energy with 67MW solar Portfolio in France

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

GenePOC announces FDA clearance for revogene™ instrument and its GBS LB test